Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT06415448
Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema
Sponsor: Ionis Pharmaceuticals, Inc.
View on ClinicalTrials.gov
Summary
The purpose of the Expanded Access Program is to provide pre-approval access of donidalorsen to eligible patients with Hereditary Angioedema (HAE) who complete the ISIS 721744-CS3 clinical trial.
Official title: Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema (HAE)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-08-05
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
Donidalorsen
Donidalorsen administered once monthly or every other month by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.